Alpha 2.0
Login Register
» Articles » PMID: 19638620

A Prospective Study of Serum Soluble CD30 Concentration and Risk of Non-Hodgkin Lymphoma

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2009 Jul 30
PMID 19638620
Citations 34
Authors
Mark P Purdue
Qing Lan
Otoniel Martinez-Maza
Martin M Oken
William Hocking
Wen-Yi Huang
Dalsu Baris
Betty Conde
Nathaniel Rothman
Affiliations
Soon will be listed here.
Abstract

Prediagnostic serum concentration of soluble CD30 (sCD30), a marker for chronic B-cell stimulation, has been associated with increased risk of developing AIDS-related non-Hodgkin lymphoma (NHL) in a recent study of HIV(+) patients. To investigate among healthy persons whether serum sCD30 is associated with NHL risk, we carried out a nested case-control study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. There was a strong dose-response relationship between prediagnostic sCD30 concentration and NHL risk among 234 cases and 234 individually matched controls (odds ratio [95% confidence interval] for second, third, and fourth quartiles vs first quartile: 1.4 [0.8-2.6], 2.2 [1.2-4.1], 4.1 [2.2-7.8]; P(trend) < .001), which persisted among cases diagnosed 6 to 10 years after providing a blood sample. Given that a similar relationship has been observed among HIV(+) patients, our findings suggest that chronic B-cell stimulation may be an important mechanism involved in B-cell lymphomagenesis among severely immunocompromised and healthy populations alike.

Citing Articles

Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.

Levin L, Ramirez C, Liao E, Guo H, Kim B, Marrogi A Cancer Epidemiol Biomarkers Prev. 2022; 32(2):233-241.

PMID: 36409490 PMC: 9905313. DOI: 10.1158/1055-9965.EPI-22-0247.

Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.

Rhee J, Birmann B, De Roos A, Epstein M, Martinez-Maza O, Breen E Int J Cancer. 2022; 152(5):865-878.

PMID: 36151863 PMC: 9812887. DOI: 10.1002/ijc.34299.

Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma.

Mancuso S, Mattana M, Santoro M, Carlisi M, Buscemi S, Siragusa S Hematol Oncol. 2022; 40(3):320-331.

PMID: 35398917 PMC: 9544175. DOI: 10.1002/hon.3002.

Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.

Hosnijeh F, Kolijn P, Casabonne D, Nieters A, Solans M, Naudin S Sci Rep. 2020; 10(1):13814.

PMID: 32796953 PMC: 7429856. DOI: 10.1038/s41598-020-70790-9.

Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.

Purdue M, Lan Q, Langseth H, Grimsrud T, Hildesheim A, Rothman N Int J Cancer. 2019; 146(12):3312-3319.

PMID: 31523805 PMC: 10123845. DOI: 10.1002/ijc.32684.

References
1.
Fisher S, Fisher R . The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004; 23(38):6524-34. DOI: 10.1038/sj.onc.1207843. View
2.
Del Prete G, De Carli M, Almerigogna F, Daniel C, DElios M, Zancuoghi G . Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995; 9(1):81-6. View
3.
Breen E, Fatahi S, Epeldegui M, Boscardin W, Detels R, Martinez-Maza O . Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol. 2006; 27(4):187-94. DOI: 10.1159/000093022. View
4.
Horie R, Watanabe T . CD30: expression and function in health and disease. Semin Immunol. 1998; 10(6):457-70. DOI: 10.1006/smim.1998.0156. View
5.
Birmann B, Mueller N, Okayama A, Hsieh C, Tachibana N, Tsubouchi H . Serologic assessment of type 1 and type 2 immunity in healthy Japanese adults. Cancer Epidemiol Biomarkers Prev. 2004; 13(8):1385-91. View